Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

European Urology

Volumn 54, Issue 1, 2008, Pages 170-180

  Debruyne, Frans ^a   Gres, Arkadij A ^b   Arustamov, Dmitrii L ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Clinical Urology MOKB   (Belarus)

^c Ministry of Health Uzbekistan   (Uzbekistan)

Author keywords

BPH; Cetrorelix gluconate; Dose ranging study; LHRH antagonist; Placebo

Indexed keywords

CETRORELIX; PLACEBO; TESTOSTERONE;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CASTRATION LIKE SIDE EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INJECTION SITE REACTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; URINE FLOW RATE; URINE RETENTION; URINE VOLUME;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 44149121728     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.03.069     Document Type: Article

References (30)

1. Rhodes T., Girman C.J., Jacobsen S.J., Roberts R.O., Guess H.A., and Lieber M.M. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 (1999) 1174-1179
2. Jacobsen S.J., Girman C.J., and Lieber M.M. Natural history of benign prostatic hyperplasia. Urology 58 6 suppl 1 (2001) 5-16
3. Tubaro A. BPH treatment: a paradigm shift. Eur Urol 49 (2006) 939-941
4. Madersbacher S., Marszalek M., Lackner J., Berger P., and Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 51 (2007) 1522-1533
5. Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M., and Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 83 (1998) 3826-3831
6. De Bellis A., Ghiandi P., Comerci A., et al. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-a in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab 81 (1996) 4148-4154
7. Begun F.P., Story M.T., Hopp K.A., Shapiro E., and Lawson R.K. Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol 153 (1995) 839-843
8. Bosch R.J.L.H., Griffiths D.J., Blom J.H.M., and Schröder F.H. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 141 (1989) 68-72
9. Eri L.M., and Tveter K.J. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 150 (1993) 359-364
10. Peters C.A., and Walsh P.C. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317 (1987) 599-604
11. Schroeder F.H., Westerhof M., Bosch R.J.L.H., and Kurth K.H. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. Eur Urol 12 (1986) 318-321
12. Gonzalez-Barcena D., Vadillo-Buenfil M., Guerra-Arguero L., Carreno J., Comaru-Schally A.M., and Schally A.V. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 24 (1994) 84-92
13. De Reijke T.M., Burk K., and Kurth K. Clinical and endocrinological results of patients treated with the LHRH antagonist (cetrorelix). Eur Urol 30 (1996) 57 abstract no. 245
14. Lepor H., Dixon C., Crawford E.D., Steidle C., and Oesterling J. A randomized double blind placebo controlled phase II study of the safety and efficacy of cetrorelix in men with BPH. J Urol 157 suppl 4 (1997) 146 abstract no. 531
15. Debruyne F., Koch G., Boyle P., et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41 (2002) 497-507
16. Debruyne F., Boyle P., Calais Da Silva F., et al. Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 45 (2004) 773-780
17. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
18. Lepor H., Williford W.O., Barry M.J., Haakenson C., and Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 160 (1998) 1358-1367
19. Hutchison A., Farmer R., Verhamme K., Berges R., and Navarrete R.V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51 (2007) 207-216 (discussion 215-6)
20. Behre H.M., Böckers A., Schlingheider A., and Nieschlag E. Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol 40 (1994) 241-248
21. Debruyne F, Tzvetkov M, Geavlettec PA. Dose ranging study of cetrorelix pamoate and placebo in the treatment of patients with symptomatic benign prostatic hyperplasia. Submitted for publication.
22. Barry M., and Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med 48 (1997) 177-189
23. Shapiro E., and Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 22 (1995) 285-287
24. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (permixon7) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29 (1996) 231-240
25. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
26. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). CMAJ 155 (1996) 1251-1259
27. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 10 (1997) 349-366
28. Walsh P.C. Treatment of benign prostatic hyperplasia. N Engl J Med 335 (1996) 586-587
29. Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L., and Rosenfeld R.G. Insulin like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79 (1994) 1410-1415
30. Debruyne F.M.J. Medical management of BPH: the debate continues. Eur Urol 50 (2006) 416-417